With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback